TY - JOUR
T1 - Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens
AU - Kashima, Yukie
AU - Togashi, Yosuke
AU - Fukuoka, Shota
AU - Kamada, Takahiro
AU - Irie, Takuma
AU - Suzuki, Ayako
AU - Nakamura, Yoshiaki
AU - Shitara, Kohei
AU - Minamide, Tatsunori
AU - Yoshida, Taku
AU - Taoka, Naofumi
AU - Kawase, Tatsuya
AU - Wada, Teiji
AU - Inaki, Koichiro
AU - Chihara, Masataka
AU - Ebisuno, Yukihiko
AU - Tsukamoto, Sakiyo
AU - Fujii, Ryo
AU - Ohashi, Akihiro
AU - Suzuki, Yutaka
AU - Tsuchihara, Katsuya
AU - Nishikawa, Hiroyoshi
AU - Doi, Toshihiko
N1 - Funding Information:
Y. Togashi has received honoraria from Ono, Bristol-Myers Squibb, Chugai, MSD and AstraZeneca, and research funding from KOTAI Biotechnologies. Y. Nakamura reported the research funding from Taiho Pharmaceutical. K. Shitara reported paid consulting or advisory roles for Astellas, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, Ono and MSD; honoraria from Novartis, AbbVie, and Yakult; and research funding from Astellas, Lilly, Ono, Sumitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD and Medi Science. T. Yoshida, N. Taoka and T. Kawase are employed at Astellas Pharma, Inc. M.Chihara and T.Wada are employed at Daiichi Sankyo Co., Ltd. K.Inaki is employed at Daiichi Sankyo RD Novare Co., Ltd. Y. Ebisuno is employed at Takeda Pharmaceutical Company Ltd. S. Tsukamoto and R.Fujii are employed at Axcelead Drug Discovery Partners Inc. A.Ohashi was an employee of Takeda Pharmaceutical Company Ltd. from 2006 to 2018, and reported paid consulting or advisory roles for Ono Pharmaceutical Company Ltd. out of this study. H. Nishikawa. has received honoraria and research funding from Ono Pharmaceutical, Bristol-Myers Squibb and Chugai Pharmaceutical outside of this work as well as research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Astellas Pharmaceutical, Sumitomo Dainippon Pharmaceutical, Asahi-Kasei, Sysmex, and BD Japan outside of this study. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
This research was supported by AMED under Grant Number JP19ak0101058, Astellas Pharma, Inc., Daiichi Sankyo Co., Ltd., and Takeda Pharmaceutical Company Ltd. The super-computing resource was provided by Human Genome Center (the Univ. of Tokyo). We thank Dr. Susumu Kobayashi, Dr. Akito Nakamura, Dr. Saomi Murai for valuable comments on the manuscript.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Single-cell level analysis is powerful tool to assess the heterogeneity of cellular components in tumor microenvironments (TME). In this study, we investigated immune-profiles using the single-cell analyses of endoscopically- or surgically-resected tumors, and peripheral blood mononuclear cells from gastric cancer patients. Furthermore, we technically characterized two distinct platforms of the single-cell analysis; RNA-seq-based analysis (scRNA-seq), and mass cytometry-based analysis (CyTOF), both of which are broadly embraced technologies. Our study revealed that the scRNA-seq analysis could cover a broader range of immune cells of TME in the biopsy-resected small samples of tumors, detecting even small subgroups of B cells or Treg cells in the tumors, although CyTOF could distinguish the specific populations in more depth. These findings demonstrate that scRNA-seq analysis is a highly-feasible platform for elucidating the complexity of TME in small biopsy tumors, which would provide a novel strategies to overcome a therapeutic difficulties against cancer heterogeneity in TME.
AB - Single-cell level analysis is powerful tool to assess the heterogeneity of cellular components in tumor microenvironments (TME). In this study, we investigated immune-profiles using the single-cell analyses of endoscopically- or surgically-resected tumors, and peripheral blood mononuclear cells from gastric cancer patients. Furthermore, we technically characterized two distinct platforms of the single-cell analysis; RNA-seq-based analysis (scRNA-seq), and mass cytometry-based analysis (CyTOF), both of which are broadly embraced technologies. Our study revealed that the scRNA-seq analysis could cover a broader range of immune cells of TME in the biopsy-resected small samples of tumors, detecting even small subgroups of B cells or Treg cells in the tumors, although CyTOF could distinguish the specific populations in more depth. These findings demonstrate that scRNA-seq analysis is a highly-feasible platform for elucidating the complexity of TME in small biopsy tumors, which would provide a novel strategies to overcome a therapeutic difficulties against cancer heterogeneity in TME.
UR - http://www.scopus.com/inward/record.url?scp=85099082298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099082298&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-79385-w
DO - 10.1038/s41598-020-79385-w
M3 - Article
C2 - 33431933
AN - SCOPUS:85099082298
VL - 11
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 341
ER -